Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial

• DOI: 10.1111/jgh.12983
• Publication Date: 2015-04-13T06:30:59Z
• Authors: Jun Heo; Seong Woo Jeon; Jin Tae Jung; Joong Goo Kwon; Dong Wook Lee; Hyun Soo Kim; Chang Hun Yang; Jeong Bae Park; Kyung Sik Park; Kwang Bum Cho; Si Hyung Lee; Byung Ik Jang
• Keywords: Esomeprazole; Concomitant; Regimen; Intention-to-treat analysis

This study aimed to validate the equivalence of first-line concomitant and hybrid regimens for Helicobacter pylori infection in an era increasing antibiotic resistance. The also assess regimen compliance.H. pylori-infected patients from six hospitals Korea were randomly assigned either or regimens. consisted 20 mg esomeprazole, 1 g amoxicillin, 500 clarithromycin, metronidazole, twice daily 10 days. a 5-day dual therapy (20 esomeprazole daily) followed by quadruple daily).Eradication rates 78.6% (187/238) 78.8% (190/241) intention-to-treat analysis, 89.8% (176/196) 89.6% (181/202) per protocol analysis. For both analyses, 95% confidence intervals fell within ± 8% margin. Adherence was better group (95.0%) than (90.1%), difference that borderline significant (P = 0.051). Adverse event higher nausea (15.8% vs 8.8%; P 0.028) regurgitation (17.6% 10.7%; 0.040).As compared with therapy, offered similar efficacy, compliance, fewer adverse events. Hybrid could be reasonable treatment option H. areas high antibiotics